Department of Defense
US Army Medical Research and Materiel Command

Fiscal Year 2003
Prostate Cancer Research Program
Awards List

Table of Contents

Introduction

The US Army Medical Research and Materiel Command (USAMRMC) is pleased to present the award list of funded projects for its fiscal year 2003 (FY03) Prostate Cancer Research Program (PCRP). Award negotiations were completed on September 30, 2004. The awards listed in this document were selected by a competitive two-tier review process. Funding decisions were based on evaluations of scientific excellence in the first review tier, followed by determinations of programmatic relevance in the second tier. These projects represent a diverse portfolio of scientific research in two categories: (1) Research Awards and (2) Training/Recruitment Awards. The Prostate Cancer Consortium Award submissions also were submitted in FY03 from those that successfully competed for the Consortium Development Award in FY01.

Congress directed $85 million in appropriations for prostate cancer research in FY03. Following receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, awards were selected, and contract negotiations were completed. A total of 213 awards was made.

The FY03 PCRP programmatic strategy called for proposals in prostate cancer research through nine program announcements released on January 27, 2003. The Research Award category included five award mechanisms: Exploration – Research Development, Exploration – Hypothesis Development, Health Disparity Research – Prostate Scholar, New Investigator, and Idea Development Awards. The Exploration – Hypothesis Development Award mechanism was designed to provide funds to support initial exploration of innovative, untested, and potentially groundbreaking concepts in prostate cancer. Exploration – Resource Development Awards support product-driven research aimed at developing critical resources needed to advance prostate cancer research. These resources may include, but are not limited to, development of animal models, cell lines, and reagents. Health Disparity Research – Prostate Scholar Awards are intended to encourage scientists or physicians who have postdoctoral and/or fellowship training, but are not yet established researchers, to focus their research efforts on the disparate burden of prostate cancer in African Americans. New Investigator Awards are targeted to investigators within 6 years of their last fellowship or postdoctoral position who have innovative ideas and new technologies applicable to prostate cancer research and treatment. Idea Development Awards are aimed at giving established prostate cancer investigators and investigators who want to move into prostate cancer research and who have preliminary data relevant to prostate cancer the necessary support and time to undertake underinvestigated areas of research. Idea Development Awards are designed to encourage innovative approaches to prostate cancer research from established investigators who are at, or above the assistant professor level or equivalent and to assist an investigator to continue to pursue, or enter into prostate cancer research.

The Training/Recruitment Award category includes Postdoctoral Traineeship, Health Disparity Training – Prostate Scholar Awards, Historically Black Colleges and Universities (HBCU) Collaborative Partnership Awards, and Physician Research Training Awards. Postdoctoral Traineeship Awards provide support for recent doctoral degree graduates to gain experience in prostate cancer research. Health Disparity Training – Prostate Scholar Awards are intended to

provide investigators in the early stages of their careers with mentored training opportunities that focus on the disparate burden of prostate cancer in African Americans. The HBCU Collaborative Partnership Awards are directed at HBCU as a means to increase the number of HBCU scientists trained as prostate cancer researchers by establishing stable, long-term partnerships between an applicant HBCU and a collaborating non-HBCU institution. The Physician Research Training Award mechanism addresses the critical shortage of physicians performing prostate cancer research and fosters their training toward becoming independent researchers. The award is designed to provide a mentored training experience for physicians who are in the last year of graduate medical education or fellowships, or within the first 3 years of their appointment as an assistant professor or equivalent.

As the funded scientists embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientific, clinical, and consumer advisors. The expertise, vision, and diversity of perspectives of all individuals who contributed to this program were vital in developing a sound investment strategy on behalf of all persons affected by prostate cancer. Their efforts and the innovative and multidisciplinary research funded through this program will guide us to a cure for prostate cancer.

Exploration: Hypothesis Development Awards

Log Number	PI Last Name	PI First Name	Institution	Title	Final Budget
PC030021	Hamill	Owen	University of Texas Medical Branch	The Stretch-Activated Ca2+-Permeable Channel: A Mechanosensory Switch for Invasiveness of Prostate Tumor Cells	$113,250
PC030061	Stone	William	East Tennessee State University	Tocotrienols and Prostate Cancer	$92,847
PC030191	Coetzee	Gerhard	USC/Norris Cancer Center and Hospital	Aberrant AR Signaling as a Function of Declining Androgen	$120,717
PC030311	Hopkins	Walter	University of Wisconsin Medical School	Inflammation, Oxidative Stress, and Preneoplasia in a Mouse Model of Chronic Bacterial Prostatitis	$109,125
PC030323	McGary	John	Baylor College of Medicine	Tumor Localization Using Radio Frequency Implants	$112,828
PC030329	Curiel	David	University of Alabama at Birmingham	An Imaging System to Monitor Efficacy of Adenovirus-Based Virotherapy Agents	$108,650
PC030362	Silverman	Robert	Cleveland Clinic Foundation	High Throughput Screening for RNase L/HPC1 Activators as Experimental Therapeutics for Prostate Cancer	$111,750
PC030370	Atashbar	Massood	Western Michigan University	Early Detection of Prostate Cancer	$102,451
PC030377	Sillerud	Laurel	University of New Mexico	Prostate Cancer Diagnosis through NMR Spectroscopy of Semen	$113,878
PC030464	Wilbur	D. Scott	University of Washington	In Vitro Assessment of a Peptide Nucleic Acid (PNA)-Peptide Conjugate Labeled with an Auger-Emitting Radionuclide for Prostate Cell Killing	$113,685
PC030480	Corey	Eva	University of Washington	Evaluation of Roles of Interferon Gamma Regulated Genes in Estradiol Inhibition of Androgen-Independent Prostate Cancer	$113,085
PC030492	Nanda	Navreet	Georgetown University Medical School	Mimicking Autoimmune Responses in Order to Attack Prostate Tumors	$116,400
PC030529	Henning	Susanne	University of California, Los Angeles	Flavonoids and DNA Repair in Prostate Cancer	$114,375
PC030537	Marker	Paul	University of Minnesota	Chromosome Engineering of a Candidate Tumor Suppressor Region	$111,375
PC030582	Nordeen	Steven	University of Colorado Health Sciences Center	HOXC Family Gene Expression in Prostate Cancer: A Mechanism Contributing to Androgen Independence	$115,254
PC030607	Webb	Paul	University of California School of Medicine	Relating Androgen Receptor Conformation to Function in Prostate Cancer Cells	$113,625

PC030679	T'ang	Anne	Children's Hospital Los Angeles	The Role of Alternative Splicing in Prostate Cancer Development	$111,600
PC030680	Reed	Brent	Louisiana State University Health Sciences Center	Effects of Altered Expression of the Adapter Protein GLUT1CBP in Normal and Malignant Prostate Cells	$108,750
PC030702	Majeska	Robert	Mount Sinai School of Medicine	Role of Bone Remodeling in Skeletal Colonization by Prostate Cancer Cells	$127,125
PC030739	Gumerlock	Paul	University of California, Davis Cancer Center	Prostate Tumor DNA in Patient Plasma: Improving Sensitivity of Methylated Sequence Detection	$111,375
PC030743	Wu	Joseph	New York Medical College	Cellular Targets of Dietary Polyphenol Resveratrol	$116,625
PC030760	Farassat	Faris	Mayo Clinic and Foundation	ERK-Directed Signal-Smart Herpes Therapy for Prostate Cancer	$129,750
PC030782	Pasternack	Gary	Johns Hopkins University School of Medicine	Target Identification for Differentiation Therapy of Prostate Cancer	$122,625
PC030859	Kumar	M. Vijay	MCG Research Institute, Inc.	Influence of p53 and PTEN/Akt on the Apoptotic Response of Prostate Cancer Cells	$90,881
PC030867	Zundel	Wayne	University of Colorado Health Sciences Center	Development of a Ubiquitin E3 Substrate Trapping Strategy	$114,017
PC030875	Schroit	Alan	University of Texas M.D. Anderson Cancer Center	Angiogenesis-Independent Neovascularization is a Major Contributor to Tumor Growth	$110,953
PC030904	Shiverick	Kathleen	University of Florida	Antioxidant Interactions with Radiotherapy in Prostate Cancer	$107,464
PC030922	Zhang	Zhuohua	The Burnham Institute	Beta-Catenin/Tcf-4/ET-1 Signaling in Tumorigenicity of Prostate Cancer	$144,000
PC031037	Oberlies	Nicholas	Research Triangle Institute	Novel Strategies for the Discovery of Anti-Prostate Cancer Specific Drug Leads from Unique Natural Product Sources	$146,625
PC031045	Wu	Lily	University of California, Los Angeles	Imaging Metastatic Prostate Cancer after Genetic Manipulation of Transcriptional Memory Regulators EZH2 and EED	$113,878
PC031080	Garabedian	Michael	New York University School of Medicine	Regulation of Normal and Malignant Prostate Growth by the Glucocorticoid Receptor	$126,740
PC031113	Vuori	Kristiina	The Burnham Institute	Molecular Mechanisms of Hormone-Refractory Prostate Cancer	$144,000
PC031151	Trumbly	Robert	Medical College of Ohio	Investigation of the Role of the UTX/Y-TLE Corepressors in Prostate Cancer	$108,845

Exploration: Resource Development Awards

Log Number	PI Last Name	PI First Name	PI Organization	Title	Final Budget
PC030140	Davis	Paul	University of California, Davis	Producing a Mouse Model to Explore the Linkages between Tocopherol Biology and Prostate Cancer	$111,375
PC030374	Denmeade	Samuel	Johns Hopkins University	Generation of Transgenic Animals Producing Ezymatically Active Prostate-Specific Antigen (PSA) in Normal and Malignant Prostate Tissue	$122,611
PC030592	Nordeen	Steven	University of Colorado Health Sciences Center	Development of Vectors for the Regulated Expression of RNAi	$115,257
PC030694	Rhim	Johng	Center for Prostate Disease Research	Development of Human Cancer Cell Models for the Study of African American Prostate Cancer	$112,275
PC030742	Williams	Briana	Louisiana State University Health Sciences Center	Rationally Designed Tissue Microarrays for the Study of Prostate Cancer Progression and Patient Outcome in African-American Men	$108,750
PC030759	Srivastava	Rakesh	University of Maryland, Baltimore	Development of Novel Drugs for Prostate Cancer Therapy	$111,305
PC030830	Ostrander	Elaine	Fred Hutchinson Cancer Research Center	Development of Immortalized Cell Lines from Hereditary Prostate Cancer Families	$127,925
PC030874	Chen	Shuo	University of Texas Health Science Center	Anti-Androgen Receptor RNA Enzyme as a Novel Therapeutic Agent for Prostate Cancer in Vivo	$107,712
PC030897	Luduena	Richard	University of Texas Health Science Center	Development of a Novel Drug for Prostate Cancer	$109,498

Health Disparity Research-Prostate Scholar Awards

Log Number	PI Last Name	PI First Name	PI Organization	Title	Final Budget
PC030067	Rayford	Walter	Louisiana State University Health Sciences Center	Health Disparity Elimination Model for Cancer	$426,000
PC030224	Jayadevappa	Ravishankar	University of Pennsylvania	Quality of Life and Cost Effectiveness of Prostate Cancer Treatment	$474,097
PC030279	Thompson	Hayley	Mount Sinai School of Medicine	Increasing Early Detection of Prostate Cancer in African American Men through a Culturally Targeted Print Intervention	$701,201
PC030327	Sharma	Sangita	University of Hawaii Cancer Research Center	Is Disparity in Prostate Cancer Rates between African-Americans and Whites Associated with Well-Done Meat Consumption and NAT1 and NAT2 Acetylator Genotypes?	$405,757
PC030378	Goldman	Radoslav	Georgetown University	DNA Repair and Ethnic Differences in Prostate Cancer Risk	$465,599
PC030633	Ingles	Sue	University of Southern California	Dietary Fat, Fat Metabolizing Genes, and Prostate Cancer Risk in African-Americans and Whites	$480,394
PC030686	Rettig	Matthew	University of California, Los Angeles	Examination of Racial Differences in the IGF Axis in African American and Caucasian Men	$457,500
PC030770	Abouta	Jessie	University of North Carolina at Chapel Hill	Racial Differences in Lifestyle Modification in Men with Newly Diagnosed Prostate Cancer	$433,936
PC030879	Plowden	Keith	University of Maryland, Baltimore	Baltimore City Faith-Based Prostate Cancer Prevention and Control Coalition	$432,528

Idea Development Awards

Log Number	PI Last Name	PI First Name	Institution	Title	Final Budget
PC030008	Rosner	William	St. Luke's Roosevelt Hospital Center	Unique Approaches to Androgen Effects on Prostate Cancer	$600,478
PC030038	Lee	Chung	Northwestern University	Immune Cells, If Rendered Insensitive to Transforming Growth Factor-Beta, Can Cure Prostate Cancer	$547,863
PC030050	Krasnykh	Victor	University of Alabama at Birmingham	Vasculature-Specific Adenovirus Vectors for Gene Therapy of Prostate Cancer	$543,750
PC030106	Ciavarra	Richard	Eastern Virginia Medical School	Novel Cancer Vaccines Engineered to Disrupt the Prostate Tumor Microenvironment	$526,750
PC030122	Feldman	David	Stanford University	Triamcinolone Therapy of Prostate Cancer: Basic Science and Clinical Trial	$589,008
PC030131	Dong	Zhongyun	University of Texas M.D. Anderson Cancer Center	A Novel Therapy System for Occult Prostate Cancer	$559,223
PC030134	Bates	Paula	University of Louisville Research Foundation, Inc.	Mechanistic Studies of Oligonucleotide Aptamers with Potent Antiproliferative and Pro-Apoptotic Activity against Prostate Cancer Cells	$551,042
PC030139	Wolf	Dieter	Harvard School of Public Health	Proteolytic Control and Function of the NKX3.1 Prostate Tumor Suppressor	$614,338
PC030147	Humphreys	Robert	Antigen Express, Inc.	Intra-Prostate Cancer Vaccine Inducer	$525,000
PC030166	McConkey	David	University of Texas M.D. Anderson Cancer Center	Regulation of Calcium Fluxes and Apoptosis by BCL-2 Family Proteins in Prostate Cancer Cells	$565,977
PC030173	Sano	Takeshi	Beth Israel Deaconess Medical Center	Selective Delivery of Adeno-Associated Viral Vectors to Prostate Cancer Cells Using Microbeads as Targetable Carriers of Viral Particles	$636,907
PC030203	Li	Rong	University of Virginia School of Medicine	A Novel Coregulator of Androgen Receptor and Its Role in Prostate Cancer	$555,000
PC030239	Sadar	Marianne	BC Cancer Agency	Development of a Potential Therapy for Prostate Cancer Based Upon the Androgen Receptor	$375,000
PC030242	Wang	Yuzhuo	BC Cancer Agency	A Novel Approach for Prostate Cancer Therapy: Application of a Unique Xenograft Model	$404,476
PC030274	Pettaway	Curtis	University of Texas M.D. Anderson Cancer Center	Determining the Invasive Index in Prostate Biopsy and Radical Prostatectomy Specimens as Determined by the Matrix Metalloproteinase to E-Cadherin Ratio	$560,613
PC030301	Hsieh	Jer-Tsong	University of Texas Southwestern Medical Center	Analysis of Morphogenic Effect of hDAB2IP on Prostate Cancer and Its Disease Correlation	$584,688

PC030310	Dennis	Leslie	University of Iowa	Sexually Transmitted Infections as a Risk Factor for Prostate Cancer among Military Personnel	$553,125
PC030328	Shields	Anthony	Wayne State University	PET Imaging of Prostate Cancer with Fluoropyrimidines	$558,000
PC030338	Weigel	Nancy	Baylor College of Medicine	Vitamin D Receptor Target Genes as Predictors of Responsiveness to Treatment with a Vitamin D Receptor Agonist	$564,374
PC030340	Liu	Wanguo	Mayo Clinic, Rochester	Clinical and Functional Analyses of p73R1 Mutations in Prostate Cancer	$547,500
PC030351	Walden	Paul	New York University School of Medicine	BTG2 Antiproliferative Gene and Prostate Cancer	$633,553
PC030368	Cox	Angela	University of Sheffield Medical School	An Investigation of Genetic Risk Factors for Prostate Cancer Using a Large Population-Based Cohort	$747,657
PC030386	Shannon	Jackilen	Portland VA Research Foundation	Fish Oil Supplementation and Fatty Acid Synthase Expression in the Prostate: A Randomized Controlled Trial	$449,980
PC030388	Dawson	Marcia	The Burnham Institute	Identification of Selective Rexinoids That Promote TR3/RXR-Alpha-Induced Prostate Cancer Cell Apoptosis	$719,806
PC030391	Swanson	Steven	University of Illinois at Chicago	Role of Growth Hormone in Prostate Cancer	$476,352
PC030402	Hossack	John	University of Virginia	High Resolution Anatomic and Elastographic Transrectal Ultrasound for Improved Diagnosis of Prostate Cancer	$527,128
PC030410	Wang	Shaomeng	University of Michigan	Structure-Based Design, Synthesis, and Testing of Non-Peptide, Cell-Permeable, Potent Small Molecule Smac Mimetics as a New Therapy for Prostate Cancer	$546,837
PC030429	Xie	Jingwu	University of Texas Medical Branch at Galveston	The Role of the Sonic Hedgehog Pathway for Prostate Cancer Progression	$566,148
PC030435	Xu	Hui	University of Alabama at Birmingham	Enhancement of Tumor Immunotherapy by Blockade of a Prostate Tumor-Derived Immunosuppressive Factor	$271,875
PC030451	Barrack	Evelyn	Henry Ford Health System	DNA Markers of Aggressive Prostate Cancer in African Americans	$536,250
PC030471	Jung	Mira	Georgetown University	Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer	$582,000
PC030481	Karin	Michael	University of California, San Diego	The Roles of I-Kappa-B Kinases in Prostate Carcinogenesis and the Effect of Their Inhibition on Survival of Prostate Tumors	$570,000
PC030482	Foty	Ramsey	University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School	Quantifying Tumor-Endothelial Cell Interaction in Organotropic Prostate Cancer	$580,724

PC030511	Lannigan	Deborah	University of Virginia	The Protein Kinase RSK Family - Roles in Prostate Cancer	$547,794
PC030519	Sheikh	M. Saeed	SUNY Upstate Medical University	COX-2 Inhibitor ON09310: A Novel Therapeutic Agent for Prostate Cancer	$569,956
PC030524	Diefenbach	Michael	Fox Chase Cancer Center	Evaluating an Interactive, Multimedia Education, and Decision Program for Early-Stage Prostate Cancer Patients in a Randomized Controlled Trial	$635,756
PC030550	Martuza	Robert	Harvard Medical School	Immunologic Approaches for Oncolytic Viral Therapy of Prostate Cancer	$648,750
PC030562	Aprikian	Armen	McGill University	Non-Steroidal Anti-Inflammatory Drug Use and Prostate Cancer Risk and Prognosis	$307,804
PC030570	Singal	Rakesh	University of Miami	Aberrant Promoter Methylation in Serum DNA as a Biomarker for Prostate Cancer	$537,275
PC030595	Ho	Shuk-Mei	University of Massachusetts Medical School	Estrogen Receptor-Beta Hypermethylation and Prostate Carcinogenesis	$596,251
PC030601	Knox	Susan	Stanford University Medical Center	Selenium is a Chemotherapeutic Agent for the Treatment of Prostate Cancer	$600,874
PC030614	Wilson	E. Lynette	New York University School of Medicine	Origin and Properties of Prostatic Stem Cells	$633,750
PC030640	Peehl	Donna	Stanford University	Development of Methodology to Maintain Primary Cultures of Normal and Malignant Human Prostatic Epithelial Cells in Vivo	$600,665
PC030653	Cooney	Kathleen	University of Michigan	Prostate Cancer Aggressiveness Genes in Hereditary Prostate Cancer	$426,695
PC030659	Day	Mark	University of Michigan	The Role of the ADAM-15 Disintegrin in E-Cadherin Proteolysis and Prostate Cancer Metastasis	$572,553
PC030682	Hayward	Simon	Vanderbilt University Medical Center	Therapy Selection by Proteomic Profiling	$275,000
PC030685	Kao	Chinghai	Indiana University	PSES-a Novel Prostate Specific Chimeric Enhancer for Prostate Cancer Gene Therapy	$564,375
PC030689	Smith	Gary	University of North Carolina at Chapel Hill	Identification of Markers of Human Vascular Dynamics Exposed in the Human Vasculature of Human Prostate Xenografts by Androgen Deprivation	$527,109
PC030698	Medrano	Estela	Baylor College of Medicine	Overexpression and Activity of the Transcriptional Co-Regulator SKI in Prostate Cancer Progression	$564,375
PC030701	Gumerlock	Paul	University of California, Davis Cancer Center	Modulation of Apoptosis-Associated and DNA Repair Genes to Enhance Radiation Therapy	$556,868
PC030704	Pinski	Jacek	USC/Norris Comprehensive Cancer Center	A Novel Therapy for Prostate Cancer Based on the Disintegrin Contortrostatin	$609,010

PC030708	Esenaliev	Rinat	University of Texas Medical Branch	Prostate Cancer Therapy with Novel Drug Delivery Technique	$566,250
PC030740	Boothman	David	Case Western Reserve University	Use of Beta-Lapachone-Encapsulated Millirods for Improved Therapy of Prostate Cancer	$573,187
PC030752	Bushman	Wade	University of Wisconsin Medical School	Sonic Hedgehog Signaling Promotes Tumor Growth	$545,625
PC030753	Xu	Liang	University of Michigan Medical School	(-)-Gossypol, a Potent Small Molecule Inhibitor of Bcl-XL as a Novel Molecular Targeted Therapy for Prostate Cancer	$560,896
PC030817	Rowley	David	Baylor College of Medicine	Role of Reactive Stroma in Prostate Cancer Progression	$523,126
PC030840	Cheng	Leo	The General Hospital Corporation dba Massachusetts General Hospital	Magnetic Resonance Spectroscopy: An Objective Technique for the Quantification of Prostate Cancer Pathologies	$648,750
PC030898	Atweh	George	Mount Sinai School of Medicine	Microtubule-Targeting Therapy for Prostate Cancer	$635,625
PC030903	Chen	Chang-Yan	Boston University School of Medicine	Modulating Apoptotic Signaling in Prostate Cancer	$605,625
PC030909	Pouliot	Jean	University of California, San Francisco	Targeting MRS-Defined Dominant Intraprostatic Lesions with Inverse-Planned High Dose Rate Brachytherapy	$540,776
PC030914	Sellers	William	Dana-Farber Cancer Institute	The Development of Novel Small Molecule Inhibitors of the Phosphoinositide-3-Kinase Pathway through High-Throughput Cell-Based Screens	$628,434
PC030923	Ahmad	Nihal	University of Wisconsin	Sanguinarine: A Novel Agent against Prostate Cancer	$545,625
PC030931	Doxsey	Stephen	University of Massachusetts Medical Center	Centrosome-Based Mechanisms, Prognostics, and Therapeutics in Prostate Cancer	$596,250
PC030943	Mukhtar	Hasan	University of Wisconsin	Cannabinoid Receptors: A Novel Target for Therapy of Prostate Cancer	$545,625
PC030958	Pisa	Pavel	Karolinska Institute	Vaccination with Naked DNA Coding for PSA (pVAX/PSA) in Combination with Electroporation in Prostate Cancer	$577,500
PC030970	Zhang	Xin	University of Tennessee Health Science Center	EWI2/PGRL, the Partner of Prostate Cancer Metastasis Suppressor KAI/CD82	$507,804
PC030977	Prochownik	Edward	Children's Hospital of Pittsburgh	Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein	$496,484
PC030987	Prendergast	George	Lankenau Institute for Medical Research	Suppression of Prostate Tumor Progression by Bin1	$375,000

PC031027	Zhang	Hui	Yale University School of Medicine	The Role of Ubiquitin E3 Ligase SCF(SKP2) in Prostate Cancer Development	$613,125
PC031034	Huang	Xue	Baylor College of Medicine	Prostate Cancer Immunotherapy Induced by Recombinant Oncolytic Viruses	$564,375
PC031038	Watabe	Kounosuke	Southern Illinois University School of Medicine	Mechanism of Tumor Metastasis Suppression by the KAI1 Gene	$534,437
PC031042	Gullapalli	Rao	University of Maryland, Baltimore	Improved Sensitivity and Specificity for Detection of Prostate Cancer	$354,000
PC031057	Adami	Hans-Olov	Karolinska Institutet	A Population-Based Study of Dietary Acrylamide and Prostate Cancer Risk	$456,347
PC031059	Hellerstein	Marc	KineMed, Inc.	A Noninvasive Biomarker for Prostate Epithelial Cell Kinetics in Vivo in Humans	$582,900
PC031091	Sinha	Akhouri	University of Minnesota	Prediction of Aggressive Human Prostate Cancer by Cathepsin B	$471,421
PC031119	Abdel-Amgeed	Asim	Tulane University School of Medicine	Functional Characterization of Two Novel Human Prostate Cancer Metastasis Related Genes	$554,525
PC031120	Benyi	Li	University of Kansas Medical Center	Inhibition of Androgen-Independent Growth of Prostate Cancer by siRNA-Mediated Androgen Receptor Gene Silencing	$532,580
PC031123	Hall	Simon	Mount Sinai School of Medicine	Construction of a Vesicular Stomatitis Virus Expressing Both a Fusogenic Glycoprotein and IL-12: A Novel Vector for Prostate Cancer Therapy	$630,770
PC031149	Chang	Chawnshang	University of Rochester	Knockout AR in Prostate	$590,625

New Investigator Awards

Log Number	PI Last Name	PI First Name	PI Organization	Title	Final Budget
PC030018	Lee	Sukyeong	Baylor College of Medicine	Molecular Chaperones in Androgen Receptor-Mediated Prostate Cancer Structural Studies of the Androgen Receptor-Hsp 90 Complex	$338,625
PC030037	Yu	Guoqiang	University of Pennsylvania	Real-Time Diffuse Optical Measurement for in Vivo PDT Dosimetry of Human Prostate	$250,000
PC030070	Mack	Philip	University of California, Davis	Targeted Prevention of Androgen Independence in Prostate Cancer: p53 Gain-of-Function Mutations	$334,077
PC030076	Ionov	Yurij	Roswell Park Cancer Institute	Identification of Prostate Cancer-Related Genes Using Inhibition of NMD in Prostate Cancer Cell Lines	$300,000
PC030092	O'Keefe	Denise	University of Pittsburgh	Genetic and Epigenetic Mechanisms Regulating Gene Expression Profiles in Prostate Cancer	$334,344
PC030130	Li	Yong	St. George Hospital	Control of Micrometastatic Prostate Cancer Using Multiple Alpha Targeted Therapy	$212,500
PC030171	Dong	Yan	Roswell Park Cancer Institute	GKLF as a Novel Target in Selenium Chemoprevention of Prostate Cancer	$396,964
PC030271	Simpson	Melanie	University of Nebraska	Role of Hyaluronan in Prostate Cancer Progression	$326,250
PC030286	Fannon	Michael	Children's Hospital Boston	Treatment of Prostate Cancer with a DBP-maf-Vitamin D Complex to Target Angiogenesis and Tumorigenesis	$363,529
PC030335	Kumar	A. Pratap	AMC Cancer Research Center	Antioxidant Prophylaxis in the Prevention of Prostatic Epithelial Neoplasia	$375,750
PC030348	Pang	Geordi	University of Toronto	Development of a Novel High Quantum Efficiency Flat Panel Detector for Image-Guided Prostate Treatment	$314,776
PC030390	Gioeli	Daniel	University of Virginia	Development of a Novel Prostate Cancer Therapy: A Tissue-Specific siRNA Delivery System for Targeted Disruption of AR Expression	$333,000
PC030478	Drotschmann	Karin	Wake Forest University Health Sciences	The Mechanistic Role of Mismatch Repair Proteins in the Transition from Indolent to Aggressive Prostate Cancer	$322,127
PC030625	Bhowmick	Neil	Vanderbilt University Medical Center	Identify the Impact of TGF-Beta Signaling on the Stroma in the Progression of Prostate Cancer	$230,000
PC030669	Nie	Dao-Tai	Wayne State University	Lipoxygenase, Angiogenicity, and Prostate Cancer Radioresistance	$336,017
PC030695	Miranti	Cynthia	Van Andel Research Institute	Integrin-Mediated Signaling in Prostate Cancer: Role of KAI1/CD82 in Regulating Integrin and Androgen Receptor Function during Metastasis	$393,440

PC030734	van Golen	Kenneth	University of Michigan Medical School	Differential Activation of the Rho GTPases in Prostate Cancer Bone Metastasis	$334,710
PC030762	Nathanson	Katherine	University of Pennsylvania School of Medicine	Identifying Somatic Genetic Changes in Prostate Cancer	$356,624
PC030775	Konety	Badrinath	University of Iowa	Use of Synthetic Nerve Grafts to Restore Cavernous Nerve Function following Prostate Cancer Surgery: In Vitro and in Vivo Studies	$329,112
PC030800	Chen	Lili	Fox Chase Cancer Center	MR Imaging-Based Treatment Planning for Radiotherapy of Prostate Cancer	$381,414
PC030916	Rini	Brian	University of California, San Francisco	CTLA-4 Blockade-Based Immunotherapy in Prostate Cancer	$292,500
PC030920	Gu	Yueqing	University of Texas at Arlington	Noninvasive Monitoring for Optimization of Therapeutic Drug Delivery by Biodegradable Fiber to Prostate Tumor	$326,756
PC030999	Elkin	Michael	Hadassah-Hebrew University Hospital	Involvement and Regulation of Heparanase in Prostate Cancer Progression	$258,750
PC031010	Spruck III	Charles	Sidney Kimmel Cancer Center	The Role of hCDC4 in Prostate Tumorigenesis	$150,000
PC031125	McAleavey	Stephen	Duke University	Enhanced Ultrasound Visualization of Brachytherapy Seeds by a Novel Magnetically Induced Motion Imaging Method	$346,150
PC031137	Cheryauka	Arvidas	University of Utah	Transurethral Ultrasound Diffraction Tomography	$335,522

Health Disparity Training - Prostate Scholar Awards

Log Number	PI Last Name	PI First Name	PI Organization	Title	Final Budget
PC030376	Touma	Sue Ellen	Weill Medical College of Cornell University	Comparative Analysis of Vitamin A (Retinol)-Regulated Genes in African-American and Caucasian Prostate Cancer Patients	$90,000
PC030666	Freedland	Stephen	Johns Hopkins University	Molecular Profiling of Prostate Cancer Precursor Lesions (PIN and PIA) in African-American and Caucasian Men	$300,000

Historically Black Colleges and Universities (HBCU) Collaborative Partnership Awards

Log Number	Last Name	First Name	Institution	Title	Final Budget
PC030462	Odedina	Folakemi	Florida A&M University	Florida A&M University (FAMU) Center for Minority Prostate Cancer Training and Research: A Collaborative Program between FAMU and the Moffitt Cancer Center	$1,064,029
PC030945	Barron	Elizabeth	Xavier University of Louisiana	Training HBCU Faculty and Students in Prostate Cancer (PC) Research: Signal Transduction and Receptor-Inhibitor Interactions in the Progress of PC	$868,562

Postdoctoral Traineeship Awards

Log Number	Last Name	First Name	Institution	Title	Final Budget
PC030012	Fang	Peng	Oregon Health and Science University	Anti-Proliferative Actions of Insulin-Like Growth Factor Binding Protein-3 in Prostate Cells	$98,000
PC030019	Bakin	Robert	Georgetown University	Inhibition of Histone Deacetylase (HDAC) Activity: Enhancement of Prostate Cancer Radiosensitivity	$98,000
PC030095	Li	Haojie	Brigham and Women's Hospital	Diet, Lifestyle Factors, and Hormone Levels as Risk Factors for Prostate Cancer	$98,000
PC030097	Jarred	Renea	Monash University	Role of Tumor Stroma in Prostate Carcinogenesis	$97,660
PC030098	Zhao	Hongjuan	Stanford University	Biomarkers of Selenium Action in Prostate Cancer	$98,000
PC030136	Mesaros	Eugen	University of Pennsylvania	Total Synthesis and Pharmacological Evaluation of the Antitumor Agent Kendomycin	$86,108
PC030176	Schere Levy	Carolina	The Burnham Institute	Vascular Addresses in Prostate Cancer	$98,000
PC030214	Hofer	Matthias	Brigham and Women's Hospital	The Role of the Metastasis-Associated Protein 1 (MTA1) in Prostate Cancer Progression	$98,000
PC030250	Evangelou	Andreas	Baylor College of Medicine	Role of Tumor Microenvironment and the FGF Signaling Axis on Differentiation and Emergence of the Neuroendocrine Phenotype in Prostate Cancer	$98,000
PC030254	Mirosevich	Janni	Vanderbilt University Medical Center	Investigating the Role of Hepatocyte Nuclear Factor-3 (HNF-3) Alpha and Beta in Prostate Cancer and Cellular Differentiation	$98,000
PC030269	Tang	Xiao-Han	Weill Medical College of Cornell University	Activation of Retinoid X Receptors by Phytanic Acid and Docohexaenoic Acid: Role in the Prevention and Therapy of Prostate Cancer	$98,000
PC030273	Chen	Bin	Dartmouth College	Tumor Vascular and Cellular Targeting for Prostate Cancer	$97,499
PC030290	Hyer	Marc	The Burnham Institute	Modulating TRAIL-Mediated Apoptosis in Prostate Cancer Using Synthetic Triterpenoids	$98,000
PC030297	Kawaguchi	Yoshiharu	Duke University Medical Center	Regulation of p53 Activity by Reversible-Acetylation in Prostate Tumor Suppression	$98,000
PC030306	Bai	Feng	University of North Carolina at Chapel Hill	Suppression of Prostate Cancer by PTEN and p18INK4c	$98,000
PC030320	Anikumar	Gopala-krishnapillai	University of California, Los Angeles	Identification and Characterization of the Ligand of Prostate-Specific Membrane Antigen	$98,000

PC030325	Podgorski	Izabela	Wayne State University School of Medicine	Cathepsin B- and K-Mediated Proteolysis in Metastasis of Human Prostate Cancer to Bone: Potential Therapeutic Targets	$98,000
PC030380	Song	Haengseok	Washington University	The Role of Nkx3.1 in Prostate Tumor Initiation	$98,000
PC030443	Horvath	Lisa	St. Vincent's Hospital	Investigation of the Role of the Wnt Signaling Pathway in Prostate Cancer: Is Secreted Frizzled-Related Protein 4 an Inhibitor of Prostate Cancer Growth?	$97,742
PC030449	Naumov	George	Children's Hospital Boston Harvard Medical School	Molecular Mechanisms of Prolonged Non-Angiogenic Dormant State	$97,928
PC030487	Sheen	Joon-Ho	Whitehead Institute for Biomedical Research	Role of Nutrient-Sensitive mTOR Signaling Pathway in Prostate Cancer Development and Growth	$98,000
PC030494	Oliva Martinez	Jose	University of Pennsylvania School of Medicine	Characterization of a Novel Intracellular Receptor for Phorbol Esters and Diacylglycerol in Prostate Cancer	$98,000
PC030508	Liu	Gang	University of Alabama at Birmingham	The Role of Mutant p53 in Progression of Prostate Cancer	$97,693
PC030515	Guo	Zhiyong	University of Maryland, Baltimore	Molecular Mechanisms of Hormone-Independent Activation of Androgen Receptor in Prostate Cancer Cells	$98,000
PC030521	Liang	Hongyan	The Burnham Institute	Identification of New EGR1 Target Genes That Regulate Radiation Responses in Prostate Cancer Cells	$98,000
PC030528	Cheltsov	Anton	The Scripps Research Institute	Computational Search for Novel Antagonists to the Metastatic Mutant Forms of the Androgen Receptor	$97,848
PC030538	Buchanan	Grant	Adelaide University and Hanson Institute	Implication of Structural Features of TAU5 in the Androgen Receptor for Prostate Cancer Progression	$97,981
PC030556	Davis	Mindy	California Institute of Technology	Structural Studies of Prostate-Specific Membrane Antigen to Aid Rational Design of Diagnostics and Therapeutics for the Treatment of Prostate Cancer	$98,000
PC030575	Johnson	Laura	University of Wisconsin-Madison	Rodent Model of Prostate Cancer Treatment Using DNA Vaccines Encoding Xenoantigens	$97,995
PC030577	Jin	Rongxian	Wayne State University	Naturally Occurring Truncated Beta3 Integrin (Alpha-IIb-Beta3 and Alpha-V-Beta3) in Prostate Cancer Metastasis	$97,828
PC030618	Cinar	Bekir	Children's Hospital Boston	Intersection of Androgen and Akt Signaling in Prostate Cancer	$97,804
PC030628	Xie	Tao	Institute for Systems Biology	Decipher the Transcriptional Program in Prostate Cancer Cells	$96,271
PC030660	Davis	Joanne	University of Michigan	The Role of Rb/E2F on AR Expression and Function in Prostate Epithelial Cells	$98,000
PC030676	Crowell	Kevin	The Burnham Institute	Human Telomerase – NMR Structure of Domains Essential for RNA Binding and Biological Function and the Identification of Small Molecule Inhibitors of hTERT	$98,000

PC030677	Koeppel	Mark	University of Wisconsin-Madison	Targeting Stromal Recruitment by Prostate Cancer Cells	$98,000
PC030711	Huss	Wendy	University of North Carolina at Chapel Hill	Origin of Neuroendocrine Cells in Recurrent Prostate Cancer	$98,000
PC030731	Betson	Martha	Massachusetts General Hospital Cancer Center	An Analysis of Rho-PKN Signaling in Prostate Cancer Using Drosophila Genetics	$98,000
PC030745	Ruiz	Maribelis	Baylor College of Medicine	Prostate Cancer Models of Genomic Instability	$98,000
PC030828	Friedrichsen	Danielle	Fred Hutchinson Cancer Research Center	Positional Cloning of an Ashkenazi Jewish Hereditary Prostate Cancer Susceptibility Locus	$98,000
PC030849	Keniry	Megan	Columbia University	Genetic Dissection of PTEN Signaling Mechanisms in Prostate Cancer	$98,000
PC030873	Dimova	Neviana	University of Kentucky Research Foundation	EGR-1 Functional Activation, Signaling, and Radiation Response in Prostate Cancer	$97,672
PC031075	Ma	Zhenyi	University of Texas Southwestern Medical Center at Dallas	Broad Spectrum Chemotherapy: A Novel Approach Using Beta-Galactosidase Activated Pro-Drugs	$98,000

Physician Research Training Awards

Log Number	Last Name	First Name	Institution	Title	Final Budget
PC031159	Mellinghoff	Ingo	University of California, Los Angeles	Regulation of Androgen Receptor Function by ErbB Receptor Tyrosine Kinases	$700,000
PC031161	Lu	Bo	Vanderbilt University	Radiation Sensitization via Inhibiting Survival of Prostate Cancer and Its Vascular Endothelium	$700,000
PC031163	Cesaretti	Jamie	Mount Sinai School of Medicine	ATM Heterozygosity and the Development of Radiation-Induced Erectile Dysfunction and Urinary Morbidity Following Radiotherapy for Prostate Cancer	$700,000
PC031175	Milowsky	Matthew	Cornell University, Weill Medical College	Targeted Therapy in Prostate Cancer: Anti-Prostate Specific Membrane Antigen Monoclonal Antibody J591	$251,130
PC031178	Garg	Madhur	Montefiore Medical Center	Antiangiogenic Therapy Targeting Endothelial Cell Receptor Tyrosine Kinase (Tie-2/Tek) in Prostate Cancer	$685,206

Fiscal Year 2003 Prostate Cancer Research Program
Peer Reviewers

Peer Reviewers	Degree	Institution/Affiliation
Abdel-Mageed, Asim	D.V.M., Ph.D.	Tulane University Health Sciences Center
Adkison, Linda	Ph.D.	Mercer University School of Medicine
Ahaghotu, Chiledum	M.D. F.A.C.S	Howard University Hospital
Ahmed, Mansoor	Ph.D.	University of Kentucky Medical Center
Arlen, Philip	M.D.	National Cancer Institute
Bahnson, Robert	M.D.	Ohio State University College of Medicine
Balk, Steven	M.D., Ph.D.	Beth Israel Deaconess Medical Center
Bartlett, Darrell		American Cancer Society
Batra, Surinder	Ph.D.	University of Nebraska Medical Center
Benos, Dale	Ph.D.	University of Alabama at Birmingham
Beuschold, George		Georgetown University Medical Center
Bielawski, Gregory		US TOO!
Bonavida, Benjamin	Ph.D.	University of California-LA School of Medicine
Bosland, Maarten	D.V.Sc., Ph.D.	New York University School of Medicine
Bova, G. Steven	M.D.	Johns Hopkins Hospital
Brach, Philip		WRAMC US TOO
Braunhut, Susan	Ph.D.	University of Massachusetts - Lowell
Bridges, Kenneth	M.D.	Harvard Medical School
Bristow, Robert	M.D., Ph.D.	University of Toronto
Brooks, James	M.D.	Stanford University Medical Center
Brown, Diane	Ph.D.	University of Medicine and Dentistry of New Jersey-School of Public Health
Bugge, Thomas	Ph.D.	NIDCR, National Institutes of Health
Buttyan, Ralph	Ph.D.	Columbia University
Calvo, Tony		Santa Cruz County Prostate Cancer Support Group
Caputi, Anthony		American Foundation for Urologic Disease
Carducci, Michael	M.D.	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carpten, John	Ph.D.	Cancer Genetics Branch, NHGRI/National Institutes of Health
Cerhan, James	M.D., Ph.D.	Mayo Clinic
Chai, Karl	Ph.D.	University of Central Florida
Chan, June	Sc.D.	University of California, San Francisco
Chang, Chawnshang	Ph.D.	University of Rochester Medical Center

Peer Reviewers	Degree	Institution/Affiliation
Chapman, John	Ph.D.	Fox Chase Cancer Center
Chatterton, Robert	Ph.D.	Northwestern University Medical School
Chavez, Noel	Ph.D.	University of Illinois, Chicago
Chen, Ching-Shih	Ph.D.	Ohio State University
Chen, Wen	Ph.D.	Greenville Hospital System & Clemson University
Chen, Yong	Ph.D.	Wake Forest University
Chinnaiyan, Arul	M.D., Ph.D.	University of Michigan
Chrysogelos, Susan	Ph.D.	University of Michigan
Clark, Barbara	Ph.D.	University of Louisville
Cohen, Stanley	M.D.	University of Medicine and Dentistry of New Jersey
Conti, Claudio	D.V.M., Ph.D.	University of Texas M.D. Anderson Cancer Center
Corey, Eva	Ph.D.	University of Washington
Costello, Les	Ph.D.	University of Maryland
Cramer, Scott	Ph.D.	Wake Forest School of Medicine
Dahiya, Rajvir	Ph.D.	University of California at San Francisco and VA Medical Center
Danks, Mary	Ph.D.	Saint Jude Children's Research Hospital
Davatzikos, Christos	Ph.D.	University of Pennsylvania
Davis, Barry	Ph.D.	Scientific Review Administrator
Dawson, Laura	M.D.	University of Toronto
Day, Mark	Ph.D.	University of Michigan
DeLucas, Lawrence	Ph.D.	University of Alabama at Birmingham
Dhir, Rajiv	M.D.	University of Pittsburgh
Diana, John	Ph.D.	Scientific Review Administrator
DiBella, Edward	Ph.D.	University of Utah
DiCioccio, Richard	Ph.D.	Roswell Park Cancer Institute
DiPaola, Robert	M.D.	The Cancer Institute of New Jersey
Djakiew, Daniel	Ph.D.	Georgetown University School of Medicine
Djeu, Julie	Ph.D.	University of San Francisco, H. Lee Moffitt Cancer Center
Dong, Jin-Tang	Ph.D.	Emory University, Winship Cancer Institute
Douglas, Joanne	Ph.D.	University of Alabama at Birmingham
Doxsey, Stephen	Ph.D.	University of Massachusetts Medical Center
Duckett, Colin	Ph.D.	University of Michigan
Eastham, James	M.D.	Memorial Sloan-Kettering Cancer Center
Edwards, Christopher	Ph.D.	Duke University Medical Center

Peer Reviewers	Degree	Institution/Affiliation
Eickelberg, William		Southeast Wisconsin Regional Cancer Center
El-Ashry, Dorraya	Ph.D.	University of Michigan Health System
Erhardt, Paul	Ph.D.	University of Toledo
Espinoza-Delgado, Igor	M.D.	National Institute of Aging, National Institutes of Health
Evans, Lemuel	Ph.D.	Scientific Review Administrator
Fawwaz, Rashid	M.D., Ph.D.	New York Presbyterian Hospital
Ferrone, Soldano	M.D., Ph.D.	Roswell Park Cancer Institute
Fisher, Darrell	Ph.D.	Radiochemical Science and Engineering, Pacific Northwest National Laboratory
Fleming, Quince		Southern Maryland Hospital
Flemington, Erik	Ph.D.	Tulane University Health Sciences Center
Foster, Barbara	Ph.D.	Roswell Park Cancer Institute
Foster, Ken		US TOO! Los Robles Regional Medical Center
Fraizer, Gail	Ph.D.	Kent State University
Frankel, Carl		US TOO!
Ganapathi, Ram	Ph.D.	Cleveland Clinic Foundation
Gardner, Thomas	M.D.	Indiana University Medical Center
Gattoni-Celli, Sebastiano	M.D.	Medical University of South Carolina
Gewirtz, David	Ph.D.	Virginia Commonwealth University
Gillespie, Richard		US TOO! Prostate Cancer-George Washington University
Gimotty, Phyllis	Ph.D.	University of Pennsylvania School of Medicine
Goins, William	Ph.D.	University of Pittsburgh School of Medicine
Graff, Jeremy	Ph.D.	Eli Lilly & Company
Graham, Charles	Ph.D.	Queen's University
Gray, David		US TOO! Prostate Cancer Survivor Support Groups
Gregor, Polly	Ph.D.	Memorial Sloan-Kettering Cancer Center
Griffith, Jeffrey	Ph.D.	University of New Mexico School of Medicine
Groshen, Susan	Ph.D.	University of Southern California-Norris Cancer Center
Gross, Alexander		American Cancer Society
Gulati, Jag	Ph.D.	Scientific Review Administrator
Gulley, James	M.D., Ph.D.	National Cancer Institute
Gumerlock, Paul	Ph.D.	University of California Davis Cancer Center
Gupta, Rishab	Ph.D.	John Wayne Cancer Institute
Hahn, Stephen	M.D.	University of Pennsylvania
Haimovitz-Friedman, Adriana	Ph.D.	Memorial Sloan-Kettering Cancer Institute

Peer Reviewers	Degree	Institution/Affiliation
Hall, Simon	M.D.	Mount Sinai School of Medicine
Hallman, D. Michael	Ph.D.	University of Texas
Hamelburg, Emanuel		Massachusetts Prostate Cancer Coalition
Harris, Robert	M.D.	Dartmouth Hitchcock Medical Center
Haun, Randy	Ph.D.	University of Arkansas for Medical Sciences
Haut, Michael	M.D.	Pennsylvania Hospital
Haynes, Peter		Tempe St. Luke's Hospital
Hein, David	Ph.D.	University of Louisville School of Medicine
Helferich, William	Ph.D.	University of Illinois
Helman, Sandy	Ph.D.	Scientific Review Administrator
Hemstreet, III, George	M.D., Ph.D.	Nebraska Medical Center
Hendrich, Suzanne	Ph.D.	Iowa State University
Heston, Warren D.W.	Ph.D.	Lerner Research Institute
Hill, Colin	Ph.D.	University of Southern California
Ho, Shuk-Mei	Ph.D.	University of Massachusetts Medical School
Holt, Shawn	Ph.D.	Medical College of Virginia Commonwealth University
Horowitz, Jonathan	Ph.D.	North Carolina State University College of Veterinary Medicine
Housley, Paul	Ph.D.	University of Southern California School of Medicine
Hovastak, Michael		Troy & Dollie Smith Cancer Center, Integris Baptist Medical Center
Hsieh, Jer-Tsong	Ph.D.	University of Texas Southwestern Medical Center at Dallas
Huang, Jiaoti	M.D., Ph.D.	University of Rochester Medical Center
Huda, Amir	Ph.D.	California State University, Fresno
Hurwitz, Arthur	Ph.D.	State University of New York Upstate Medical Center
Ittmann, Michael	M.D., Ph.D.	Houston VA Medical Center
Jain, Aridaman		American Cancer Society
Jarrard, David	M.D.	University of Wisconsin
Jeng, Meei-Huey	Ph.D.	Indiana University
Johnson, Carolyn	Ph.D.	Tulane University School of Public Health and Tropical Medicine
Johnson, Michael	Ph.D.	Georgetown University, Lombardi Cancer Center
Johnson, Steven	Ph.D.	University of Pennsylvania
Jonekos, Stan		US TOO! International
Jones, David		US TOO! International
Kan-Mitchell, June	Ph.D.	Karmanos Cancer Institute

Peer Reviewers	Degree	Institution/Affiliation
Kasper, Susan	Ph.D.	Vanderbilt University Medical Center
Kast, W. Martin	Ph.D.	Cardinal Bernardin Cancer Center, Loyola University Chicago
Kazanietz, Marcelo	Ph.D.	University of Pennsylvania School of Medicine
Keefer, Garrett	Ph.D.	Scientific Review Administrator
Keller, Evan	D.V.M., Ph.D.	University of Michigan
Keller, Jonathan	Ph.D.	National Cancer Institute-Frederick
Keri, Ruth	Ph.D.	Case Western Reserve University
Kilbridge, Kerry	M.D.	University of Virginia
Kim, Hyeong-Reh	Ph.D.	Wayne State University
Kinch, Michael	Ph.D.	MedImmune Inc.
Kobus, William		US TOO! International
Kothari, Manish	Ph.D.	Synarc
Kuchta, Robert	Ph.D.	University of Colorado at Boulder
Kulp, Donald		Pennsylvania Prostate Cancer Coalition (PPCC)
Kumar, M. Vijay	Ph.D.	Medical College of Georgia
Kung, Hsing-Jien	Ph.D.	University of California-Davis Cancer Center
Kurt, Robert	Ph.D.	Lafayette College
Kwak-Kim, Joanne	M.D.	Finch University of Health Sciences/The Chicago Medical School
Kwon, Eugene	M.D.	Mayo Clinic and Comprehensive Cancer Center
Lafrado, Louis	Ph.D.	L&D Associates Consulting Group
LaHann, Thomas	Ph.D.	Mitretek Systems
Lamb, Dolores	Ph.D.	Baylor College of Medicine
Lange, Carol	Ph.D.	University of Minnesota Cancer Center
Leach, Fredrick	M.D., Ph.D.	Baylor College of Medicine
Lee, Chung	Ph.D.	Northwestern University Medical School
Lee, Eva	Ph.D.	Georgia Institute of Technology, School of Industrial and Systems Engineering
Lewis, Lionel	M.D.	Dartmouth College
Lin, Sue-Hwa	Ph.D.	The University of Texas M.D. Anderson Cancer Center
Lin, Young	D.V.M., Ph.D.	Ohio State University
Lingrel, Jerry	Ph.D.	University of Cincinnati College of Medicine
Liu, Brian	Ph.D.	Brigham and Women's Hospital
Locker, Joseph	M.D., Ph.D.	Albert Einstein College of Medicine
Lokeshwar, Balakrishna	Ph.D.	University of Miami, School of Medicine

Peer Reviewers	Degree	Institution/Affiliation
Lokeshwar, Vinata	Ph.D.	University of Miami School of Medicine
Lopaczynski, Wlodek	M.D., Ph.D.	BBI Biotech Research Laboratories
Lorenzi, Matthew	Ph.D.	Bristol-Myers Squibb
Lu, Michael	Ph.D.	Brigham and Women's Hospital
Lum, Clark	Ph.D.	Scientific Review Administrator
Lum, Lawrence	M.D., D.Sc.	Roger Williams Medical Center
Macoska, Jill	Ph.D.	The University of Michigan
Madalengoitia, Jose	Ph.D.	University of Vermont
Mandelson, Margaret	Ph.D., M.P.H.	Group Health Cooperative of Puget Sound
Manfredi, James	Ph.D.	Ruttenberg Cancer Center, Mount Sinai School of Medicine
Mannarino, Maria	M.D.	Scientific Review Administrator
Marcus, Aaron	M.D.	Weill Medical College-Cornell University
Marfyak, Jan		Pennsylvania Prostate Cancer Coalition
Martignetti, John	M.D., Ph.D.	Pediatrics & Cancer Center, Mount Sinai School of Medicine
Massik, George		US TOO! of Western New York
Masters, Joseph		US TOO! of Western New York
McBain, John	Ph.D.	Dartmouth Medical School
McKee, Herbert		US TOO! International
McLaughlin, William		US Too! of Western New York
McLeskey, Sandra	Ph.D.	University of Maryland Baltimore
Meadows, Gary	Ph.D.	Washington State University College of Pharmacy
Mehta, Rajeshwari	Ph.D.	University of Illinois Medical Center
Meier, G. Patrick	Ph.D.	Medical University of South Carolina
Mergo, Patricia	M.D.	University of Florida College of Medicine
Meruelo, Daniel	Ph.D.	New York University Medical Center
Miaux, Yves	M.D.	Synarc
Lum, Lawrence	M.D., D.Sc.	Roger Williams Medical Center
Miller, Donald	M.D., Ph.D.	James Graham Brown Cancer Center
Morris, Patricia	Ph.D.	The Rockefeller University
Mukhtar, Hasan	Ph.D.	University of Wisconsin, Med SC Center
Mulhern, Sally	Ph.D.	Scientific Review Administrator
Murillo, Rudy		US TOO! International
Nanda, Navreet	Ph.D.	Georgetown University
Narayan, Satya	Ph.D.	University of Florida

Peer Reviewers	Degree	Institution/Affiliation
Narla, Mohandas	Sc.D.	New York Blood Center, Lindsley F. Kimball Research Institute
Neckers, Leonard	Ph.D.	National Cancer Institute
Nelson, Mark	Ph.D.	University of Arizona
Niles, Richard	Ph.D.	Marshall University School of Medicine
Nishimura, Michael	Ph.D.	University of Chicago Medical Center
Noguchi, Constance	Ph.D.	National Institute of Diabetes & Digestive & Kidney Diseases of the National Institutes of Health
Nutter, John	Ph.D.	Scientific Review Administrator
O'Connell, Peter	Ph.D.	Virginia Commonwealth University
Oh, William	M.D.	Dana Farber Cancer Institute
O'Hara, Dennis		Man to Man
Olive, Peggy	Ph.D.	British Columbia Cancer Research Centre
Olsen, Phillip		US TOO! International
Olumi, Aria	M.D.	Beth Israel Deaconess Medical Center
Ornstein, David	M.D.	University of California, Irvine
O'Rourke, Maureen	Ph.D.	University of North Carolina, Greensboro
Ove, Peter	Ph.D.	Scientific Review Administrator
Parra-Medina, Deborah	Ph.D., M.P.H.	University of South Carolina
Pawlicki, Todd	Ph.D.	Stanford University School of Medicine
Peehl, Donna	Ph.D.	Stanford University Medical Center
Penn, Linda	Ph.D.	Ontario Cancer Institute
Perales, Miguel-Angel	M.D.	Memorial Sloan-Kettering Cancer Center
Perez-Stable, Carlos	Ph.D.	Miami VA Medical Center
Perz, Catherine	Ph.D.	University of Houston Victoria
Peschel, Richard	M.D., Ph.D.	Yale-New Haven Hospital
Pettaway, Curtis	M.D.	The University of Texas M.D. Anderson Cancer Center
Prochownik, Edward	M.D., Ph.D.	Children's Hospital of Pittsburgh
Raffo, Anthony	Ph.D.	Columbia University
Ramsay, Alistair	Ph.D.	Louisiana State University Health Sciences Center
Rane, Stanley	Ph.D.	Fujisawa Research Institute of America
Reddy, E. Premkumar	Ph.D.	Fels Research Institute, Temple University School of Medicine
Richardson, Barbara	Ph.D.	Baylor College of Medicine
Riese, II, David	Ph.D.	Purdue University
Rinker-Schaeffer, Carrie	Ph.D.	University of Chicago
Ritter, Mark	M.D., Ph.D.	University of Wisconsin-Madison

Peer Reviewers	Degree	Institution/Affiliation
Roberts, Jr., Charles	Ph.D.	Oregon Health and Science University
Robinson, Bruce		US TOO! International
Rodgers, Charles	Ph.D.	Scientific Review Administrator
Ross, Jeffrey	M.D.	McArdle Laboratory
Rowley, David	Ph.D.	Baylor College of Medicine
Rubin, Mark	M.D.	Brigham and Women's Hospital
Rui, Hallgeir	M.D., Ph.D.	Georgetown University, Lombardi Cancer Center
Sadar, Marianne	Ph.D.	British Columbia Cancer Agency
Sandberg, Howard	Ph.D.	Scientific Review Administrator
Sande, Brad		Olean Man-to-Man, Prostate Cancer Education and Support Group
Sartor, Oliver	M.D.	Louisiana State University Medical School
Saw, Cheng	Ph.D.	University of Pittsburgh Medical Center Cancer Pavilion
Schneider, Barbara	Ph.D.	Louisiana State University Health Sciences Center
Sens, Donald	Ph.D.	School of Medicine and Health Sciences
Shah, Girish	Ph.D.	Texas Tech University Health Science Center
Shain, Sydney	Ph.D.	University of Texas Health Science Center
Shekhar, Malathy	Ph.D.	Karmanos Cancer Institute
Sheng, Shijie	Ph.D.	Wayne State University School of Medicine
Shi, Yufang	D.V.M., Ph.D.	Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey
Sholes, Westley		California Prostate Cancer Coalition
Showalter, Paul		South Shore Hospital Prostate Support Group
Siegal, Gene	M.D., Ph.D.	University of Alabama at Birmingham
Signoretti, Sabina	M.D.	Dana Farber Cancer Institute
Sikes, Robert	Ph.D.	University of Delaware
Skramstad, Gary		US TOO! St Cloud
Sloboda, Walter	M.A.	Scientific Review Administrator
Slovin, Susan	M.D., Ph.D.	Memorial Sloan-Kettering Cancer Center
Smith, Allen	M.S.	Scientific Review Administrator
Smith, F. Terrance		The Survivors Association
Sommers, Bernard		PAACT, Inc.
Song, Chang	Ph.D.	University of Minnesota Medical School
Spielmann, H. Peter	Ph.D.	University of Kentucky
Stamler, Arthur		Us Too! of Greenville South Carolina

Peer Reviewers	Degree	Institution/Affiliation
Stanton, Francis		Prostate Cancer Networking Group (Cincinnati)
Stevens, Craig	M.D., Ph.D.	University of Texas, MD Anderson Cancer Center
Stevens, Ernest		Anne Arundel Medical Cancer Prostate Support Group
Stewart, Juarine	Ph.D.	Clark Atlanta University
Stierman, Joseph		Walter Reed Army Medical Center, US TOO!
Stokes, Nathaniel		Anne Arundel Medical Cancer Prostate Support Group
Strawbridge, Lee		US TOO! University of Pittsburgh Cancer Institute Chapter
Sun, Zijie	Ph.D.	Stanford University Medical Center
Swain, Edwin		Keowee Key Prostate Cancer Support Group
Swanson, Steven	Ph.D.	University of Illinois at Chicago
Syed, Viqar	Ph.D.	University of Massachusetts
Sylvester, Diane	Ph.D.	Mitretek Systems
Tang, Dean	M.D., Ph.D.	University of Texas M.D. Anderson Cancer Center
Thomas, Peter	Ph.D.	Boston University School of Medicine
Thomas, T.J.	Ph.D.	University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School
Tiwari, Raj	Ph.D.	New York Medical College
Trevor, Katrina	Ph.D.	Arizona Cancer Center
Turner, Timothy	Ph.D.	Tuskegee University
Tuszynski, George	Ph.D.	Temple University
Umbreit, Jay	M.D., Ph.D.	Emory University, Winship Cancer Institute
Velicer, Wayne	Ph.D.	University of Rhode Island
Vessella, Robert	Ph.D.	University of Washington Medical Center
Walsh, Raymond		Walter Reed Army Medical Center US TOO! Support Group
Wang, Bing-Cheng	Ph.D.	Case Western Reserve University School of Medicine
Wang, Shaomeng	Ph.D.	University of Michigan
Wang, Zhou	Ph.D.	Northwestern University Medical School
Ware, Joy	Ph.D.	Medical College of Virginia, Virginia Commonwealth University
Watkins Bruner, Deborah	Ph.D.	Fox Chase Cancer Center
Wayda, Michael		US TOO!
Weber, Georg	M.D., Ph.D.	New England Medical Center
Weber, H. Christian	M.D.	Boston University School of Medicine
Weeks, James		US TOO! Prostate Cancer Survivor Support
Weigel, Nancy	Ph.D.	Baylor College of Medicine
Weiss, Robert	M.D.	Yale University School of Medicine

Peer Reviewers	Degree	Institution/Affiliation
Welch, Danny	Ph.D.	University of Alabama, Birmingham
Whiting, Bruce	Ph.D.	Washington University School of Medicine
Williams, Briana	Ph.D.	Louisiana State University Health Sciences Center
Wilson, Elizabeth	Ph.D.	University of North Carolina Chapel Hill
Woloschak, Gayle	Ph.D.	Northwestern University, Feinberg School of Medicine
Wu, Lily	M.D., Ph.D.	David Geffen School of Medicine at UCLA
Wu, T.C.	M.D., Ph.D.	Johns Hopkins University School of Medicine
Xia, Ping	Ph.D.	University of California San Francisco Comprehensive Cancer Center
Xu, Yan	Ph.D.	Cleveland Clinic Foundation
Yang, Yu-Chung	Ph.D.	Case Western Reserve University
Yao, Yin	Ph.D.	Johns Hopkins School of Public Health
Yeaman, Charles	Ph.D.	University of Iowa
Young, Charles	Ph.D.	Mayo Clinic/Foundation
Young, Joseph	Ph.D.	Scientific Review Administrator
Zebovitz, Eugene	Ph.D.	Scientific Review Administrator
Zelefsky, Michael	M.D.	Memorial Sloan-Kettering Cancer Center
Zeleniuch-Jacquotte, Anne	M.D.	New York University School of Medicine
Zhang, Jian-Ting	Ph.D.	Indiana University School of Medicine, Cancer Research
Zimmer, Stephen	Ph.D.	Markey Cancer Center, University of Kentucky

Fiscal Year 2003 Prostate Cancer Research Program
Integration Panel (IP) Members

IP Members	Degree	Institution/Affiliation
Waldman, Frederic (Chair)	M.D., Ph.D.	University of California at San Francisco
Vogelzang, Nicholas (Chair Elect)	M.D.	University of Chicago
Liebert, Monica (Member-at-Large)	Ph.D.	American Urological Association
Prins, Gail (*Member-at-Large)*	Ph.D	University of Illinois at Chicago
Carey, Thomas	Ph.D.	University of Michigan
deKernion, Jean	M.D.	University of California, Los Angeles School of Medicine
Dreicer, Robert	M.D.	The Cleveland Clinic Foundation
Kantoff, Philip	M.D.	Dana-Farber Cancer Institute
Lieberman, Ronald	M.D.	National Cancer Institute
Roach, Mack III	M.D.	University of California, San Francisco
Simons, Virgil		The Prostate Net
Smith, Joseph Jr	M.D.	Vanderbilt University School of Medicine
Soule, Howard	Ph.D.	CaP CURE
Van Auken, Wendell	MBA	University of California, San Francisco Cancer Center

Fiscal Year 2003 Prostate Cancer Research Program
Ad-Hoc Programmatic Reviewers

Ad Hoc Reviewers	Degree	Institution/Affiliation
Carey, Robert		Georgia Prostate Cancer Coalition and Men Coming Together
Freeman, Michael	Ph.D.	Children's Hospital Boston
Price, Marva	DrPH, RN, FNP, CS	Duke University School of Nursing
Ratliff, Timothy L.	Ph.D	University of Iowa
Rennie, Paul	Ph.D.	Vancouver General Hospital
Sanda, Martin G.	M.D.	University of Michigan
Vijayakumar, Srinivasan	M.D., D.M.R.T.	University of California, Davis Cancer Center

Glossary of Terms

Exploration – Hypothesis Development Award: The intent of the Exploration – Hypothesis Development Award is to provide funds to support initial exploration of innovative, untested, and potentially groundbreaking concepts in prostate cancer. Exploration – Hypothesis Development Awards should (but are not required to) precede the articulation of a hypothesis or may provide the scientific rationale upon which a new hypothesis can be based. The award is designed to provide investigators with the opportunity to pursue serendipitous observations. The Exploration – Hypothesis Development Award is not intended to support ongoing work; therefore, the existence of preliminary data suggests that the research would be more appropriately submitted to a different award mechanism. Successfully completed Exploration – Hypothesis Development Awards are expected to lead to high-risk, potentially high-gain future research endeavors for this and other funding agencies. Projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b)(4)[1].

Exploration – Resource Development Award: The intent of the Exploration – Resource Development Award is to support product-driven research aimed at developing critical resources needed to advance prostate cancer research. These resources may include, but are not limited to, development of animal models, cell lines, and reagents. The award also will support studies whose purpose is to develop or refine analytical or experimental methodologies and to discover, develop, or screen new or existing therapeutics. Due to the developmental nature of this award, preliminary data are not required, but may be included if available, to address the feasibility of the resource to be developed. In either case, Exploration – Resource Development Award proposals must apply a sound scientific rationale and logical reasoning based on existing knowledge to the development of the proposed product. Projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b)(4)[2] or eligible for expedited review (45 CFR 46.110, 21 CFR 56.110)[3].

Health Disparity Research – Prostate Scholar Award: The intent of the Health Disparity Research – Prostate Scholar Award is intended to encourage investigators at assistant professor level or equivalent to focus their research efforts on the disparate burden of prostate cancer in African Americans. These awards will require the active involvement of a collaborator who is an established prostate cancer researcher. The ultimate goal of these awards is to resolve the disparity in prostate cancer incidence, morbidity, and mortality between African Americans and other ethnic groups. The proposal must explicitly express how the proposed research is related to a health disparity issue.

Health Disparity Training – Prostate Scholar Award: The intent of the Health Disparity Training – Prostate Scholar Award is intended to provide investigators in the **early stages** of their careers with training opportunities (under the guidance of a designated mentor) that focus

---

1 Title 32, Code of Federal Regulations, Part 219, Section 101(b)(4). Research involving collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, is considered to be exempt under 32 CFR 219.101(b)(4).

2 *Ibid.*

3 For additional information, refer to the U.S. Department of Health and Human Services' Office of Human Research Protection website at http://www.hhs.gov/ohrp.

on the disparate burden of prostate cancer in African Americans. The ultimate goal of these awards is to resolve the disparity in prostate cancer incidence, morbidity, and mortality between African Americans and other ethnic groups. The proposal must explicitly express how the proposed research is related to a health disparity issue. Under this award mechanism, investigators may apply for Predoctoral Traineeships, Postdoctoral Traineeships, or Postresidency Traineeships.

Idea Development Award: The intent of the Idea Development Award is to encourage innovative approaches to prostate cancer research from established prostate cancer investigators and those investigators who are at the assistant professor level or equivalent who want to move into the prostate cancer field. Idea Development Award research should represent the start of something new, creating or introducing a unique or unusual approach to the study of prostate cancer. This research may represent a new paradigm, challenge existing paradigms, or look at an existing problem from a new perspective. All Idea Development proposals must include preliminary data.

New Investigator Award: The intent of the New Investigator Award is to support innovative ideas and technology from investigators in the early phases of their careers (within 6 years of their last fellowship or postdoctoral position). The applicant must be an independent investigator with access to appropriate research facilities and may not have received nonmentored funding exceeding $100,000 in aggregate as a Principal Investigator (PI) from extramural sources. Proposals are not required to have preliminary data. Although this research is inherently risky and does not require preliminary data, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or a critical review and analysis of the literature.

Physician Research Training Award: The intent of the Physician Research Training Award is to provide a mentored training experience that will prepare physicians who are in the last year of graduate medical education or fellowships, or within the first 3 years of their appointment as an assistant professor or equivalent, for an independent career in prostate cancer research. A training program appropriate to the area of study (basic, translational, or population-based sciences) of the Principal Investigator (PI) must be part of the application; coursework and/or seminars in key areas such as statistics, bioethics, and/or relevant basic science disciplines within his or her area of research interest also may be included. Aggressive protection of the PI's time (minimum of 60% effort) for research also is provided through the award. A mentor with an established research program in prostate cancer research must be involved with the PI's training.

Postdoctoral Traineeship Award: The intent of the Postdoctoral Traineeship Award is to enable recent doctoral degree graduates with limited postdoctoral experience (i.e., 3 years or less at the time of proposal submission) either to extend ongoing research related to prostate cancer or to broaden the scope of their research to include work relevant to prostate cancer under the guidance of a designated mentor. The focus of these awards is on the applicant, the mentor, and the training environment. Eligible applicants must have successfully defended a doctoral thesis and completed all academic requirements at the time of award negotiation.